Background: T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) primarily presenting on the skin is an extremely rare entity with only sporadic cases reported in the literature. Methods: We here report an extraordinary case of primary cutaneous THRLBCL with self-healing and 24 months of follow-up. Results: The lesion was a dermohypodermal/subcutaneous circumscribed ulcerated nodosity. Histological examination with immunohistochemical, molecular analysis and comparative genomic hybridization were performed. A complete staging was negative for secondary involvement. Conclusion: Our case is remarkable because it is the second well-documented primary cutaneous THRLBCL in which we observed a complete self-regression of skin lesions without recurrences or dissemination of the disease. According to the literature, we highlight that the tumoral microenvironment, in our case, could play a relevant role in stopping lymphoma growth. Furthermore, this case supports the observation that THRLBCL primarily presenting on the skin shows an overall good prognosis.

Keywords:
T-cell/histiocyte-rich B-cell lymphoma, Cutaneous presentation, Tumoral microenvironment
1.
De Wolf-Peeters C, Delabie J, Campo E, Jaffe ES, Delsol G: T cell/histiocyte-rich large B-cell lymphoma; in Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds): WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, IARC Press, 2008, pp 238–239.
2.
Venizelos ID, Tatsiou ZA, Mandala E: Primary cutaneous T-cell-rich B-cell lymphoma: a case report and literature review. Acta Dermatovenerol Alp Panonica Adriat 2008;17:177–181.
3.
Li S, Griffin CA, Mann RB, Borowitz MJ: Primary cutaneous T-cell-rich B-cell lymphoma: clinically distinct from its nodal counterpart? Mod Pathol 2001;14:10–13.
4.
Ramsay AD, Smith WJ, Isaacson PG: T-cell-rich B-cell lymphoma. Am J Surg Pathol 1988;12:433–443.
5.
Delabie J, Vandenberghe E, Kennes C, Verhoef G, Foschini MP, Stul M, Cassiman JJ, De Wolf-Peeters C: Histiocyte-rich B-cell lymphoma: a distinct clinicopathologic entity possibly related to lymphocyte predominant Hodgkin’s disease, paragranuloma subtype. Am J Surg Pathol 1992;16:37–48.
6.
Sander CA, Kaudewitz P, Kutzner H, Simon M, Schirren CG, Sioutos N, Cossman J, Plewig G, Kind P, Jaffe ES: T-cell-rich B-cell lymphoma presenting in skin. J Cutan Pathol 1996;23:101–108.
7.
Osborne BM, Butler JJ, Pugh WC: The value of immunophenotyping on paraffin sections in the identification of T-cell rich B-cell large-cell lymphoma: lineage confirmed by JH rearrangement. Am J Surg Pathol 1990;14:933–938.
8.
Khan SM, Cottrell BJ, Millward-Sadler GH, Wright DH: T-cell-rich B-cell lymphoma presenting as liver disease. Histopathology 1993;23:217–234.
9.
Macon WR, Williams MF, Greer JP: T-cell-rich B-cell lymphomas: a clinicopathologic study of 19 cases. Am J Surg Pathol 1992;16:351–363.
10.
Dommann SN, Dommann-Scherrer CC, Zimmerman D, Dours-Zimmermann MT, Hassam S, Burg G: Primary cutaneous T-cell-rich B-cell lymphoma: a case report with a 13-year follow-up. Am J Dermopathol 1995;17:618–624.
11.
Gogstetter D, Brown M, Seab J, Scott G: Angiocentric primary cutaneous T-cell-rich B-cell lymphoma: a case report and review of the literature. J Cutan Pathol 2000;27:516–525.
12.
Dunphy CH, Nalass GT: Primary cutaneous T-cell-rich B-cell lymphoma with low cytometric immunophenotipyc findings. Arch Pathol Lab Med 1999;123:1236–1240.
13.
Krishnan J, Wallberg K, Frizzera G: T-cell-rich large B-cell lymphoma: a study of 30 cases, supporting its histologic heterogeneity and lack of clinical distinctiveness. Am J Surg Pathol 1994;18:455–465.
14.
Take H, Kubota K, Fukuda T, Shinonome S, Ishikawa O, Shirakura T: An indolent type of Epstein-Barr virus-associated T-cell-rich B-cell lymphoma of the skin: report of a case. Am J Hematol 1996;52:221–223.
15.
Watabe H, Kawakami T, Soma Y, Baba T, Mizoguchi M: Primary cutaneous T-cell-rich B-cell lymphoma in a zosteriform distribution associated with Epstein-Barr virus infection. J Dermatol 2002;29:748–753.
16.
Arai E, Sakurai M, Nakayama H, Morinaga S, Katayama I: Primary cutaneous T-cell-rich B-cell lymphoma. Br J Dermatol 1993;129:196–200.
17.
Kamarashev J, Dummer R, Schmidt MH, Kempf W, Kurrer MO, Burg G: Primary cutaneous T-cell-rich B-cell lymphoma and Hodgkin’s disease in patient with Gardner’s syndrome. Dermatology 2000;201:362–365.
18.
Wollina U: Complete response of a primary cutaneous T-cell-rich B-cell lymphoma treated with interferon α2a. J Cancer Res Clin Oncol 1998;124:127–129.
19.
Ng CS, Chan JKC, Hui PK, Ian WH: Large B-cell lymphomas with high content of reactive T-cells. Hum Pathol 1989;20:1145–1154.
20.
Lim MS, Beaty M, Sorbara L, Cheng RZ, Pittaluga S, Raffeld M, Jaffe ES: T-cell/histiocyte-rich large B-cell lymphoma, a heterogeneous entity with derivation from germinal center B cells. Am J Surg Pathol 2002;26:1458–1466.
21.
Pittaluga S, Jaffe ES: T cell/histiocyte-rich large B-cell lymphoma. Haematologica 2009;5:352–356.
22.
Stein H, Bob R: Is Hodgkin lymphoma just another B-cell lymphoma? Curr Hematol Malig Rep 2009;4:125–128.
23.
Ratei R, Hummel M, Anagnostopoulos I, Jähne D, Arnold R, Dörken B, Mathas S, Benter T, Dudeck O, Ludwig WD, Stein H: Common clonal origin of an acute B-lymphoblastic leukemia and a Langerhans’ cell sarcoma: evidence of hematopoietic plasticity. Haematologica 2010;95:1461–1466.
24.
Pittaluga S, Wilson WH, Jaffe ES: Lymphomatoid granulomatosis; in Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds): WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, IARC Press, 2008, pp 247–249.
25.
Herrero B, Sanchez-Aguilera A, Paris MA: Lymphoma microenvironment: culprit or innocent? Leukemia 2008;22:49–58.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.